NCT07088185

Brief Summary

The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
3mo left

Started Dec 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Dec 2024Aug 2026

Study Start

First participant enrolled

December 1, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

June 17, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 28, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Expected
Last Updated

July 28, 2025

Status Verified

July 1, 2025

Enrollment Period

1.4 years

First QC Date

June 17, 2025

Last Update Submit

July 19, 2025

Conditions

Lung Fibrosis

Keywords

Pulmonary outcomesLung fibrosis

Outcome Measures

Primary Outcomes (3)

  • FVC

    Forced vital capacity (FVC).

    One month

  • FEV1

    Forced expiratory volume in the first second (FEV1)

    One month

  • The FEV1 on FVC

    The ratio between FEV1 and FVC

    One month.

Study Arms (2)

Control group

OTHER

This group will recieve only routine medical care.

Other: Routine medical care

Pulmonary rehabilitation group

OTHER

Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine medical care.

Other: Routine medical careOther: Pulmonary rehabilitation

Interventions

Routine medical careOTHER

Routine medical care

Control groupPulmonary rehabilitation group
Pulmonary rehabilitationOTHER

Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.

Pulmonary rehabilitation group

Eligibility Criteria

Age35 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • both gender.
  • patients with cystic fibrosis.

You may not qualify if:

  • severe chronic disorders.
  • heart failure
  • respiratory failure.
  • age less than 35 or older than 55 years old.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

South valley university

Qina, Egypt

Location

MeSH Terms

Conditions

Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Lung Diseases, InterstitialLung DiseasesRespiratory Tract DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

June 17, 2025

First Posted

July 28, 2025

Study Start

December 1, 2024

Primary Completion

May 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

July 28, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

I will not share it outside the primary research group.

Locations

EG(1)